Radius Health (RDUS) Reduced to "Sell" at Zacks Investment Research

Zacks Investment Research has downgraded the shares of Radius Health (NASDAQ: RDUS) from an assessment to a sales evaluation in a research note published on Thursday.

According to Zacks, "Radius got a boost with the approval of the main drug Tymlos, Tymlos sales continue to gain ground, with total prescriptions accounting for 22% of the total market for anabolic osteoporosis in the United States ( based on Months Months Therapy, TRx PMOT) in the quarter Tymlos is expected to be covered for approximately 274 million lives insured, accounting for about 95% of the commercial USA and 64% of Medicare insured lives from 1 January 2019. However Radius was arrested when the CHMP reported a negative trend vote for the MAA following a re-examination of its top-flight drug Tymlos, followed by the CHMP saying it had maintained its negative opinion on the 39; AIC to its formal final vote While the postmenopausal osteoporosis market provides significant commercial potential, it is rather crowded given the presence of products such as Prolia di A mgen and Forteo di Lilly. The shares have underperformed the sector in the last six months. "

Many other equity research analysts have also published reports on the stock. Cowen reiterated a holding assessment of Radius Health's shares in a research note on Thursday 18 October. BidaskClub updated Radius Health's shares from a strong sales rating to a sales rating in a research note on Tuesday 2 October. JPMorgan Chase & Co. lowered their price target on Radius Health shares from $ 59.00 to $ 52.00 and set an overweight on the stock in a research note on Friday 2 November. Finally, ValuEngine lowered Radius Health's shares from a valuation to a sales valuation in a research note on Wednesday, January 2. Two research analysts rated the stock with a sales rating, four assigned a hold rating, and five assigned a rating to the company. The stock currently has a Hold consensus rating and an average price target of $ 44.50.

On Thursday, RDUS sold $ 0.50 during trading, reaching $ 16.44. The company had a trading volume of 523,800 shares, compared to its average volume of 729,037. The stock has a market capitalization of $ 755.50 million, a P / E ratio of -2.83 and a beta of 0.94. Radius Health has a minimum of one year of $ 12.81 and a maximum of one year of $ 41.16. The company has a current ratio of 5.50, a quick ratio of 5.39 and a debt / equity ratio of 1.85.

Radius Health (NASDAQ: RDUS) has published its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($ 1.09) EPS for the quarter, exceeding the consensus estimate of $ 1.26 for $ 0.17. The company recorded revenue of $ 27.7 million in the quarter, compared to analysts' expectations of $ 26.00 million. Radius Health had a negative net margin of 346.67% and a negative return on equity of 140.79%. Revenues from the company rose by 105.2% compared to the same quarter last year. During the same period of the previous year, the company published ($ 1.31) EPS. On average, equity research analysts predict that Radius Health will post a -5.17 EPS for the current fiscal year.

In other news, the largest shareholder Growth N. V. Biotech has acquired 60,000 shares of the stock in a transaction dated Friday, December 14th. The shares were purchased at an average cost of $ 15.64 per share, for a total transaction of $ 938.400.00. Following the purchase, the insider now directly owns 6,650,276 shares of the company, for a value of $ 104,010,316.64. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, available on the SEC website. In addition, VP Joseph Francis Kelly acquired 3,000 shares of the stock in a transaction dated Monday, December 17. The shares were purchased at an average price of $ 15.71 per share, for a total transaction of $ 47.130.00. Following the completion of the purchase, the vice president now owns 3,000 shares of the company directly, worth $ 47,130. The disclosure for this purchase can be found here. Insiders have acquired a total of 123,000 company shares worth $ 1,854,330 in the last quarter. Employees own 3.32% of the company's shares.

Institutional investors have recently added or reduced their holdings in the company. Belpointe Asset Management LLC has acquired a new position in shares of Radius Health in the third quarter of the value of approximately $ 110,000. Cubist Systematic Strategies LLC increased its stake in Radius Health shares by 9,303.0% during the second quarter. Cubist Systematic Strategies LLC now owns 9,403 shares of the biopharmaceutical company's shares valued at $ 277,000 after the purchase of an additional 9,303 shares during the last quarter. Pacer Advisors Inc. acquired a new position in Radius Health shares in the third quarter of approximately $ 186,000. Verition Fund Management LLC acquired a new position in shares of Radius Health in the third quarter of approximately $ 208,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of Radius Health in the third quarter of approximately $ 264,000.

About Radius Health

Radius Health, Inc., a biopharmaceutical company, develops and markets endocrine therapies in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing a transdermal patch of abaloparatide, a short-acting patch formulation of abaloparatide that is in a phase III clinical trial for the treatment of postmenopausal women with osteoporosis; RAD1901, a down-regulator / degradation of the selective estrogenic receptor, found in the Phase I clinical trial for the treatment of metastatic breast cancer; and RAD140, a selective non-steroidal androgen receptor modulator that is in a Phase I clinical trial for breast cancer.

History in focus: market capitalization

Get a free copy of the Zacks research report on Radius Health (RDUS)

For more information on Zacks Investment Research research offers, visit

Get news and ratings for Radius Health Daily – Enter your email address below to receive a summary daily summary of the latest analyst news and ratings for Radius Health and companies associated with the FREE daily newsletter.


Post Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.